FIGURE 6.

Schematic representation of the CDX2/miR-125b/CBFβ pathway in the pathogenesis of hematopoietic malignancies and ATRA-dependent therapy. Left row, in the AML pathogenesis, increasing CDX2 levels activate miR-125b, which in turn inhibits CBFβ translation, thereby counteracting myeloid cell differentiation and promoting leukemogenesis. Right row, once differentiation ensues, for example, under ATRA induction, CDX2 activity decreases, reducing the transcription of miR-125b. This mechanism further contributes to ATRA-dependent therapy through high expression of target genes, mediated at least in part by CBFβ.